H. Lundbeck Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Charl van Zyl

Chief executive officer

kr.39.6m

Total compensation

CEO salary percentage	6.8%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.8yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Charl van Zyl's remuneration changed compared to H. Lundbeck's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr.40m	kr.3m	kr.2b

Compensation vs Market: Charl's total compensation ($USD5.71M) is above average for companies of similar size in the Danish market ($USD2.12M).

Compensation vs Earnings: Insufficient data to compare Charl's compensation with company performance.

CEO

Charl van Zyl (56 yo)

less than a year

Tenure

kr.39,600,000

Compensation

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charl van Zyl	President & CEO	less than a year	kr.39.60m	no data
Joerg Hornstein	CFO & Executive VP of Corporate Functions	1.8yrs	kr.10.90m	0.0023% DKK 733.0k
Lars Bang	Executive Vice President of Product Development & Supply	5.3yrs	kr.10.10m	0.038% DKK 12.3m
Per Luthman	Executive Vice President of Research & Development	5.3yrs	kr.11.30m	0.014% DKK 4.5m
Tarek Samad	Senior VP & Head of Research	3yrs	no data	no data
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	no data	no data
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	no data	no data
Dianne Holto	Executive Vice President of People & Organization	less than a year	no data	no data
Ole Chrintz	Senior Vice President of International Markets	no data	no data	no data
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.3yrs	no data	no data
Bjorn Mogensen	Senior Vice President of Group Finance	1.8yrs	no data	no data
Jose Molinuevo	VP & Head of Experimental Medicine	no data	no data	no data

1.8yrs

Average Tenure

57.5yo

Average Age

Experienced Management: HLUN A's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Lars Rasmussen	Independent Chairman	11.3yrs	kr.1.70m	0.010% DKK 3.3m
Lene Skole-Sorensen	Deputy Chairman	9.3yrs	kr.1.20m	0.0062% DKK 2.0m
Jeffrey Berkowitz	Independent Director	6.2yrs	kr.1.20m	no data
Lars Holmqvist	Director	9.3yrs	kr.600.00k	0.0076% DKK 2.4m
Jakob Riis	Director	1.2yrs	kr.450.00k	0.0055% DKK 1.8m
Ilse Wenzel	Independent Director	3.2yrs	kr.70.00k	no data
Santiago Arroyo	Independent Director	3.2yrs	kr.1.00m	no data
Camilla Andersson	Employee Representative Director	2.2yrs	kr.400.00k	0.00010% DKK 32.3k
Dorte Clausen	Employee Representative Director	2.2yrs	kr.400.00k	0.00011% DKK 35.5k
Hossein Armandi	Employee Representative Director	2.2yrs	kr.400.00k	no data
Lasse Skibsbye	Employee Representative Director	2.2yrs	kr.400.00k	no data

3.2yrs

Average Tenure

57yo

Average Age

Experienced Board: HLUN A's board of directors are considered experienced (3.2 years average tenure).

H. Lundbeck Management

Management criteria checks 1/4

Key information

Recent management updates

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Take Care Before Diving Into The Deep End On H. Lundbeck A/S (CPH:HLUN A)

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

First quarter 2023 earnings released: EPS: kr.0.89 (vs kr.0.41 in 1Q 2022)

Full year 2022 earnings: Revenues in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for 2022

Investor sentiment improves as stock rises 15%

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck's (CPH:HLUN A) Soft Earnings Are Actually Better Than They Appear

Less than half of directors are independent

Third quarter 2022 earnings released

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Less than half of directors are independent

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age